Overview

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether blocking the mineralocorticoid receptor, alone, or in combination with the calcimimetic cinacalcet, can lower parathyroid hormone and calcium levels in primary hyperparathyroidism.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
Amiloride
Cinacalcet
Cinacalcet Hydrochloride
Eplerenone
Spironolactone